Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1507787 | 0.86 | TSHR (0.48) | ENPP2SMN1; SMN2GRM4GSK3BSLC6A2 | |
| SCHEMBL30961611 | 0.86 | TSHR (0.48) | ENPP2SMN1; SMN2GRM4GSK3BSLC6A2 | |
| SCHEMBL9197340 | 0.84 | SMN1; SMN2 (0.57) | CYP19A1CYP11B1CYP11B2CYP17A1SMN1; SMN2 | |
| SCHEMBL3075742 | 0.81 | SMN1; SMN2 (0.43) | CYP19A1SMN1; SMN2GRM4VNN1KCNA5 | |
| SCHEMBL30251242 | 0.80 | CYP19A1 (0.53) | CYP19A1CYP11B1CYP11B2CYP17A1CYP3A4 | |
| SCHEMBL17338939 | 0.80 | CYP19A1 (0.53) | CYP19A1CYP11B1CYP11B2CYP17A1CYP3A4 | |
| SCHEMBL6746768 | 0.80 | CYP17A1 (0.42) | CYP19A1CYP11B1CYP11B2CYP17A1CYP3A4 | |
| SCHEMBL17064353 | 0.79 | CA1 (0.45) | CYP3A4ENPP2GRM4GSK3BTNF | |
| SCHEMBL18286274 | 0.76 | S1PR1 (0.39) | CLK4ENPP2GRM4GSK3BVNN1 | |
| SCHEMBL4384901 | 0.76 | IDO1 (0.43) | CYP19A1LRRK2CLK4GRM5CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126835-B1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2026-02-18 | — | — | EP | disclosed |
| US-12516038-B2 | Inhibitors of antigen presentation by HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2026-01-06 | — | — | US | disclosed |
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| EP-4126835-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | Janssen Pharmaceutica NV (BE) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021198283-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-07 | — | — | WO | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| EP-2040698-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | CYP19A1 688/4885CYP11B1 371/4885CYP11B2 302/4885 |
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | HLA-DRB1, CD74, HLA-C | CYP19A1 3518/4885CYP11B1 2151/4885CYP11B2 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.